Who are Nicardipine + Verapamil + Nitroglycerin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicardipine-verapamil-nitroglycerin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nicardipine + Verapamil + Nitroglycerin — Competitive Intelligence Brief

Nicardipine + Verapamil + Nitroglycerin (Nicardipine + Verapamil + Nitroglycerin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antihypertensive/antianginal (calcium channel blockers + nitrate). Area: Cardiovascular.

marketed Combination antihypertensive/antianginal (calcium channel blockers + nitrate) L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nicardipine + Verapamil + Nitroglycerin (Nicardipine + Verapamil + Nitroglycerin) — Peng Roc Chen, MD. This combination reduces cardiac workload and improves coronary blood flow by blocking calcium channels (nicardipine and verapamil) and dilating blood vessels (nitroglycerin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicardipine + Verapamil + Nitroglycerin TARGET	Nicardipine + Verapamil + Nitroglycerin	Peng Roc Chen, MD	marketed	Combination antihypertensive/antianginal (calcium channel blockers + nitrate)	L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antihypertensive/antianginal (calcium channel blockers + nitrate) class)

Peng Roc Chen, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicardipine + Verapamil + Nitroglycerin — Competitive Intelligence Brief. https://druglandscape.com/ci/nicardipine-verapamil-nitroglycerin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab